{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T13:55:20Z","timestamp":1679320520114},"reference-count":60,"publisher":"Bentham Science Publishers Ltd.","issue":"20","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2021,1,14]]},"abstract":"<jats:sec>\n<jats:title \/>\n<jats:p>Heart Failure (HF) is recognized as an important public health concern worldwide,\nespecially in developed countries, due to its high rate of morbidity and mortality. Although new\npharmacological and non-pharmacological agents have improved the clinical sequelae of HF in\npatients, its mortality remains high, especially among the elderly. Erythropoietin (EPO), a glycoprotein,\nbesides its traditional role in promoting erythropoiesis and production of erythroid progenitors, its\nbeneficial role in reducing infarct area and improving heart function through EPO-induced antiapoptotic\nand antioxidant effects have been increasingly recognized. This review gathers the evidence\nto date about the effectiveness of EPO in HF patients. In addition to the growing evidence of EPO in\nthe treatment of HF in the animal studies for improving cardiac function and infarct size, more clinical\nstudies are needed to assess the role of EPO treatment in the management of HF.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389557520999200728155543","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T06:37:47Z","timestamp":1596004667000},"page":"2080-2089","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Application of Erythropoietin in Chronic Heart Failure Treatment"],"prefix":"10.2174","volume":"20","author":[{"given":"Atena","family":"Pourtaji","sequence":"first","affiliation":[{"name":"Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vajiheh","family":"Jahani","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[{"name":"Halal Research Center of IRI, FDA, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thozhukat","family":"Sathyapalan","sequence":"additional","affiliation":[{"name":"Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, York Y0105DD, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir Hooshang","family":"Mohammadpour","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/713773607","volume":"10","author":"De Boer RA","year":"2003","unstructured":"De Boer RA; Pinto YM; Van Veldhuisen DJ; The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: The role of microvascular growth and abnormalities. Microcirculation (New York, NY: 1994)., 2003,10(2),113-126"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/eurheartj\/19.6.842","volume":"19","author":"McMurray J.J.","year":"1998","unstructured":"McMurray J.J.; Petrie M.C.; Murdoch D.R.; Davie A.P.; Clinical epidemiology of heart failure: Public and private health burden. Eur Heart J 1998,19(Suppl. 1),9-16","journal-title":"Eur Heart J"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1001\/jama.293.1.90","volume":"293","author":"Maiese K.","year":"2005","unstructured":"Maiese K.; Li F.; Chong Z.Z.; New avenues of exploration for erythropoietin. JAMA 2005,293(1),90-95","journal-title":"JAMA"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ehj.2003.11.017","volume":"25","author":"van der Meer P.","year":"2004","unstructured":"van der Meer P.; Voors A.A.; Lipsic E.; van Gilst W.H.; van Veldhuisen D.J.; Erythropoietin in cardiovascular diseases. Eur Heart J 2004,25(4),285-291","journal-title":"Eur Heart J"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jacc.2006.04.007","volume":"48","author":"van der Meer P.","year":"2006","unstructured":"van der Meer P.; Lipsic E.; Erythropoietin: Repair of the failing heart. J Am Coll Cardiol 2006,48(1),185-186","journal-title":"J Am Coll Cardiol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1093\/ndt\/gfh800","volume":"20","author":"Rossert J.","year":"2005","unstructured":"Rossert J.; Eckardt K-U.; Erythropoietin receptors: Their role beyond erythropoiesis. Nephrol Dial Transplant 2005,20(6),1025-1028","journal-title":"Nephrol Dial Transplant"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1042\/CS20100305","volume":"120","author":"Mastromarino V","year":"2011","unstructured":"Mastromarino V; Volpe M; Musumeci MB; Autore C; Conti E; Erythropoietin and the heart: Facts and perspectives. Clinical science (London, England: 1979)., 2011,120(2),51-63"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1001\/archinte.164.3.262","volume":"164","author":"Henry D.H.","year":"2004","unstructured":"Henry D.H.; Bowers P.; Romano M.T.; Provenzano R.; Epoetin alfa. Clinical evolution of a pleiotropic cytokine. Arch Intern Med 2004,164(3),262-276","journal-title":"Arch Intern Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jacc.2006.04.008","volume":"48","author":"Hirata A.","year":"2006","unstructured":"Hirata A.; Minamino T.; Asanuma H.; Fujita M.; Wakeno M.; Myoishi M.; Tsukamoto O.; Okada K.; Koyama H.; Komamura K.; Takashima S.; Shinozaki Y.; Mori H.; Shiraga M.; Kitakaze M.; Hori M.; Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol 2006,48(1),176-184","journal-title":"J Am Coll Cardiol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1161\/CIRCULATIONAHA.105.568402","volume":"113","author":"Li L.","year":"2006","unstructured":"Li L.; Takemura G.; Li Y.; Miyata S.; Esaki M.; Okada H.; Kanamori H.; Khai N.C.; Maruyama R.; Ogino A.; Minatoguchi S.; Fujiwara T.; Fujiwara H.; Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 2006,113(4),535-543","journal-title":"Circulation"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"H522","DOI":"10.1152\/ajpheart.00357.2006","volume":"292","author":"Prunier F.","year":"2007","unstructured":"Prunier F.; Pfister O.; Hadri L.; Liang L.; Del Monte F.; Liao R.; Hajjar R.J.; Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol 2007,292(1),H522-H529","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=12","first-page":"641","volume":"32","author":"Cari\u0107 T.","year":"2008","unstructured":"Cari\u0107 T.; Derek O.; Cari\u0107 D.; Effect of erythropoietin in a patient with severe congestive heart failure--a case report. Coll Antropol 2008,32(2),641-643","journal-title":"Coll Antropol"},{"key":"ref=13","first-page":"619","volume":"20","author":"Li L.","year":"2011","unstructured":"Li L.; Yang G.D.; Duan W.; Zhang H.C.; Mechanisms underlying protective effect of erythropoietin on acute decompensated congestive heart failure in mice. Zhongguo Xin Yao Zazhi 2011,20(7),619-624","journal-title":"Zhongguo Xin Yao Zazhi"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.ahj.2007.12.036","volume":"155","author":"Belonje A.M.","year":"2008","unstructured":"Belonje A.M.; Voors A.A.; van Gilst W.H.; Anker S.D.; Slart R.H.; Tio R.A.; Zijlstra F.; van Veldhuisen D.J.; HEBE III investigators. Effects of erythropoietin after an acute myocardial infarction: Rationale and study design of a prospective, randomized, clinical trial (HEBE III). Am Heart J 2008,155(5),817-822","journal-title":"Am Heart J"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S0008-6363(03)00468-1","volume":"59","author":"Smith K.J.","year":"2003","unstructured":"Smith K.J.; Bleyer A.J.; Little W.C.; Sane D.C.; The cardiovascular effects of erythropoietin. Cardiovasc Res 2003,59(3),538-548","journal-title":"Cardiovasc Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1093\/eurheartj\/ehm177","volume":"28","author":"Westenbrink B.D.","year":"2007","unstructured":"Westenbrink B.D.; Lipsic E.; van der Meer P.; van der Harst P.; Oeseburg H.; Du Marchie Sarvaas G.J.; Koster J.; Voors A.A.; van Veldhuisen D.J.; van Gilst W.H.; Schoemaker R.G.; Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 2007,28(16),2018-2027","journal-title":"Eur Heart J"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"20655","DOI":"10.1074\/jbc.M314099200","volume":"279","author":"Parsa C.J.","year":"2004","unstructured":"Parsa C.J.; Kim J.; Riel R.U.; Pascal L.S.; Thompson R.B.; Petrofski J.A.; Matsumoto A.; Stamler J.S.; Koch W.J.; Cardioprotective effects of erythropoietin in the reperfused ischemic heart: A potential role for cardiac fibroblasts. J Biol Chem 2004,279(20),20655-20662","journal-title":"J Biol Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/j.jacc.2006.08.031","volume":"48","author":"Lipsic E.","year":"2006","unstructured":"Lipsic E.; Schoemaker R.G.; van der Meer P.; Voors A.A.; van Veldhuisen D.J.; van Gilst W.H.; Protective effects of erythropoietin in cardiac ischemia: From bench to bedside. J Am Coll Cardiol 2006,48(11),2161-2167","journal-title":"J Am Coll Cardiol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejheart.2007.10.008","volume":"10","author":"Lipsic E.","year":"2008","unstructured":"Lipsic E.; Westenbrink B.D.; van der Meer P.; van der Harst P.; Voors A.A.; van Veldhuisen D.J.; Schoemaker R.G.; van Gilst W.H.; Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur J Heart Fail 2008,10(1),22-29","journal-title":"Eur J Heart Fail"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1136\/hrt.2008.161091","volume":"95","author":"van der Meer P.","year":"2009","unstructured":"van der Meer P.; Groenveld H.F.; Januzzi J.L.; van Veldhuisen D.J.; Erythropoietin treatment in patients with chronic heart failure: A meta-analysis. Heart 2009,95(16),1309-1314","journal-title":"Heart"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/MAJ.0b013e318210041d","volume":"342","author":"Li X-J.","year":"2011","unstructured":"Li X-J.; Wang X-W.; Du Y-J.; Protective effects of erythropoietin on myocardial infarction in rats: The role of AMP-activated protein kinase signaling pathway. Am J Med Sci 2011,342(2),153-159","journal-title":"Am J Med Sci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1042\/CS20100305","volume":"120","author":"Mastromarino V.","year":"2011","unstructured":"Mastromarino V.; Volpe M.; Musumeci M.B.; Autore C.; Conti E.; Erythropoietin and the heart: Facts and perspectives. Clin Sci (Lond) 2011,120(2),51-63","journal-title":"Clin Sci (Lond)"},{"key":"ref=23","first-page":"154","volume":"2","author":"Gobe G.C.","year":"2013","unstructured":"Gobe G.C.; Morais C.; Vesey D.A.; Johnson D.W.; Use of high-dose erythropoietin for repair after injury: A comparison of outcomes in heart and kidney. J Nephropathol 2013,2(3),154-165","journal-title":"J Nephropathol"},{"key":"ref=24","first-page":"1978","volume":"1813","author":"Zhang X.","year":"2011","unstructured":"Zhang X.; Tang N.; Hadden T.J.; Rishi A.K.; Akt, FoxO and regulation of apoptosis. Biochimica et Biophysica Acta (BBA)-. Mol Cell Res 2011,1813(11),1978-1986","journal-title":"Mol Cell Res"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10557-005-3189-6","volume":"19","author":"Moon C.","year":"2005","unstructured":"Moon C.; Krawczyk M.; Paik D.; Lakatta E.G.; Talan M.I.; Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: Dose response and therapeutic window. Cardiovasc Drugs Ther 2005,19(4),243-250","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1124\/jpet.105.094854","volume":"316","author":"Moon C.","year":"2006","unstructured":"Moon C.; Krawczyk M.; Paik D.; Coleman T.; Brines M.; Juhaszova M.; Sollott S.J.; Lakatta E.G.; Talan M.I.; Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J Pharmacol Exp Ther 2006,316(3),999-1005","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.cardfail.2010.02.008","volume":"16","author":"Angeli F.S.","year":"2010","unstructured":"Angeli F.S.; Amabile N.; Burjonroppa S.; Shapiro M.; Bartlett L.; Zhang Y.; Virmani R.; Chatterjee K.; Boyle A.; Grossman W.; Yeghiazarians Y.; Prolonged therapy with erythropoietin is safe and prevents deterioration of left ventricular systolic function in a porcine model of myocardial infarction. J Card Fail 2010,16(7),579-589","journal-title":"J Card Fail"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00395-004-0455-x","volume":"99","author":"Shi Y.","year":"2004","unstructured":"Shi Y.; Rafiee P.; Su J.; Pritchard K.A.; Tweddell J.S.; Baker J.E.; Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels. Basic Res Cardiol 2004,99(3),173-182","journal-title":"Basic Res Cardiol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jacc.2005.03.044 PMID: 15992646","volume":"46","author":"van der Meer P.","year":"2005","unstructured":"van der Meer P.; Lipsic E.; Henning R.H.; Boddeus K.; van der Velden J.; Voors A.A.; van Veldhuisen D.J.; van Gilst W.H.; Schoemaker R.G.; Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005,46(1),125-133","journal-title":"J Am Coll Cardiol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/01.fjc.0000140209.04675.c3","volume":"44","author":"Lip\u0161ic E.","year":"2004","unstructured":"Lip\u0161ic E.; van der Meer P.; Henning R.H.; Suurmeijer A.J.; Boddeus K.M.; van Veldhuisen D.J.; van Gilst W.H.; Schoemaker R.G.; Timing of erythropoietin treatment for cardioprotection in ischemia\/reperfusion. J Cardiovasc Pharmacol 2004,44(4),473-479","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000142723","volume":"112","author":"Prunier F.","year":"2009","unstructured":"Prunier F.; Pottier P.; Clairand R.; Mercier A.; Hajjar R.J.; Planchon B.; Furber A.; Chronic erythropoietin treatment decreases post-infarct myocardial damage in rats without venous thrombogenic effect. Cardiology 2009,112(2),129-134","journal-title":"Cardiology"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1006\/jmcc.1996.0193","volume":"28","author":"Olivetti G.","year":"1996","unstructured":"Olivetti G.; Quaini F.; Sala R.; Lagrasta C.; Corradi D.; Bonacina E.; Gambert S.R.; Cigola E.; Anversa P.; Acute myocardial infarction in humans is associated with activation of programmed myocyte cell death in the surviving portion of the heart. J Mol Cell Cardiol 1996,28(9),2005-2016","journal-title":"J Mol Cell Cardiol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1755-1536-1-7","volume":"1","author":"Ruvinov E.","year":"2008","unstructured":"Ruvinov E.; Sharabani-Yosef O.; Nagler A.; Einbinder T.; Feinberg M.S.; Holbova R.; Douvdevani A.; Leor J.; Transplantation of genetically engineered cardiac fibroblasts producing recombinant human erythropoietin to repair the infarcted myocardium. Fibrogenesis Tissue Repair 2008,1(1),7","journal-title":"Fibrogenesis Tissue Repair"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1161\/01.CIR.0000078635.89229.8A","volume":"108","author":"Cai Z.","year":"2003","unstructured":"Cai Z.; Manalo D.J.; Wei G.; Rodriguez E.R.; Fox-Talbot K.; Lu H.; Zweier J.L.; Semenza G.L.; Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 2003,108(1),79-85","journal-title":"Circulation"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.1073\/pnas.0630444100","volume":"100","author":"Calvillo L.","year":"2003","unstructured":"Calvillo L.; Latini R.; Kajstura J.; Leri A.; Anversa P.; Ghezzi P.; Salio M.; Cerami A.; Brines M.; Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA, 2003,100(8),4802-4806","journal-title":"Proc Natl Acad Sci USA,"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"10526","DOI":"10.1073\/pnas.97.19.10526","volume":"97","author":"Brines M.L.","year":"2000","unstructured":"Brines M.L.; Ghezzi P.; Keenan S.; Agnello D.; de Lanerolle N.C.; Cerami C.; Itri L.M.; Cerami A.; Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA, 2000,97(19),10526-10531","journal-title":"Proc Natl Acad Sci USA,"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1006\/mvre.2002.2426","volume":"64","author":"Jaquet K.","year":"2002","unstructured":"Jaquet K.; Krause K.; Tawakol-Khodai M.; Geidel S.; Kuck K-H.; Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002,64(2),326-333","journal-title":"Microvasc Res"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"9733","DOI":"10.1523\/JNEUROSCI.21-24-09733.2001","volume":"21","author":"Shingo T.","year":"2001","unstructured":"Shingo T.; Sorokan S.T.; Shimazaki T.; Weiss S.; Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 2001,21(24),9733-9743","journal-title":"J Neurosci"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1182\/blood-2003-01-0223","volume":"102","author":"Heeschen C.","year":"2003","unstructured":"Heeschen C.; Aicher A.; Lehmann R.; Fichtlscherer S.; Vasa M.; Urbich C.; Mildner-Rihm C.; Martin H.; Zeiher A.M.; Dimmeler S.; Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003,102(4),1340-1346","journal-title":"Blood"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"11612","DOI":"10.1073\/pnas.1930406100","volume":"100","author":"Moon C.","year":"2003","unstructured":"Moon C.; Krawczyk M.; Ahn D.; Ahmet I.; Paik D.; Lakatta E.G.; Talan M.I.; Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA 2003,100(20),11612-11617","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.bbrc.2004.10.064","volume":"325","author":"Zhao W.","year":"2004","unstructured":"Zhao W.; Lu L.; Chen S.S.; Sun Y.; Temporal and spatial characteristics of apoptosis in the infarcted rat heart. Biochem Biophys Res Commun 2004,325(2),605-611","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1136\/mp.56.6.362 PMID: 14645700","volume":"56","author":"Feng Q.Z.","year":"2003","unstructured":"Feng Q.Z.; Li T.D.; Wei L.X.; Qiao X.; Yi J.; Wang L.; Yang T.S.; Tempero-spatial dissociation between the expression of Fas and apoptosis after coronary occlusion. MP. Mol Pathol 2003,56(6),362-367","journal-title":"Mol Pathol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ejheart.2007.11.009","volume":"10","author":"Frantz S.","year":"2008","unstructured":"Frantz S.; Vallabhapurapu D.; Tillmanns J.; Brousos N.; Wagner H.; Henig K.; Ertl G.; M\u00fcller A.M.; Bauersachs J.; Impact of different bone marrow cell preparations on left ventricular remodelling after experimental myocardial infarction. Eur J Heart Fail 2008,10(2),119-124","journal-title":"Eur J Heart Fail"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1161\/01.RES.0000218454.76784.66","volume":"98","author":"Dawn B.","year":"2006","unstructured":"Dawn B.; Guo Y.; Rezazadeh A.; Huang Y.; Stein A.B.; Hunt G.; Tiwari S.; Varma J.; Gu Y.; Prabhu S.D.; Kajstura J.; Anversa P.; Ildstad S.T.; Bolli R.; Postinfarct cytokine therapy regenerates cardiac tissue and improves left ventricular function. Circ Res 2006,98(8),1098-1105","journal-title":"Circ Res"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/eurjhf\/hfp183","volume":"12","author":"Piepoli M.F.","year":"2010","unstructured":"Piepoli M.F.; Vallisa D.; Arbasi M.; Cavanna L.; Cerri L.; Mori M.; Passerini F.; Tommasi L.; Rossi A.; Capucci A.; Cardiac Study Group. Bone marrow cell transplantation improves cardiac, autonomic, and functional indexes in acute anterior myocardial infarction patients (Cardiac Study). Eur J Heart Fail 2010,12(2),172-180","journal-title":"Eur J Heart Fail"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/mt.2009.85","volume":"17","author":"Yeghiazarians Y.","year":"2009","unstructured":"Yeghiazarians Y.; Zhang Y.; Prasad M.; Shih H.; Saini S.A.; Takagawa J.; Sievers R.E.; Wong M.L.; Kapasi N.K.; Mirsky R.; Koskenvuo J.; Minasi P.; Ye J.; Viswanathan M.N.; Angeli F.S.; Boyle A.J.; Springer M.L.; Grossman W.; Injection of bone marrow cell extract into infarcted hearts results in functional improvement comparable to intact cell therapy. Mol Ther 2009,17(7),1250-1256","journal-title":"Mol Ther"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10557-010-6263-7","volume":"24","author":"Angeli F.S.","year":"2010","unstructured":"Angeli F.S.; Amabile N.; Shapiro M.; Mirsky R.; Bartlett L.; Zhang Y.; Virmani R.; Chatterjee K.; Boyle A.; Grossman W.; Yeghiazarians Y.; Cytokine combination therapy with erythropoietin and granulocyte colony stimulating factor in a porcine model of acute myocardial infarction. Cardiovasc Drugs Ther 2010,24(5-6),409-420","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.cardfail.2010.03.008","volume":"16","author":"Yeghiazarians Y.","year":"2010","unstructured":"Yeghiazarians Y.; Khan M.; Angeli F.S.; Zhang Y.; Jahn S.; Prasad M.; Mirsky R.; Shih H.; Minasi P.; Boyle A.; Grossman W.; Cytokine combination therapy with long-acting erythropoietin and granulocyte colony stimulating factor improves cardiac function but is not superior than monotherapy in a mouse model of acute myocardial infarction. J Card Fail 2010,16(8),669-678","journal-title":"J Card Fail"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1097\/01.fjc.0000211766.59636.0d","volume":"47","author":"Olea F.D.","year":"2006","unstructured":"Olea F.D.; Vera Janavel G.; De Lorenzi A.; Cuniberti L.; Yannarelli G.; Cabeza Meckert P.; Cearras M.; Laguens R.; Crottogini A.; High-dose erythropoietin has no long-term protective effects in sheep with reperfused myocardial infarction. J Cardiovasc Pharmacol 2006,47(6),736-741","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.ejheart.2004.03.012","volume":"6","author":"van der Meer P.","year":"2004","unstructured":"van der Meer P.; Lipsic E.; Henning R.H.; de Boer R.A.; Suurmeijer A.J.; van Veldhuisen D.J.; van Gilst W.H.; Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur J Heart Fail 2004,6(7),853-859","journal-title":"Eur J Heart Fail"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1172\/JCI200524283","volume":"115","author":"Dimmeler S.","year":"2005","unstructured":"Dimmeler S.; Zeiher A.M.; Schneider M.D.; Unchain my heart: The scientific foundations of cardiac repair. J Clin Invest 2005,115(3),572-583","journal-title":"J Clin Invest"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/nature02446","volume":"428","author":"Murry C.E.","year":"2004","unstructured":"Murry C.E.; Soonpaa M.H.; Reinecke H.; Nakajima H.; Nakajima H.O.; Rubart M.; Pasumarthi K.B.; Virag J.I.; Bartelmez S.H.; Poppa V.; Bradford G.; Dowell J.D.; Williams D.A.; Field L.J.; Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004,428(6983),664-668","journal-title":"Nature"},{"key":"ref=53","author":"Makkar R.","year":"2002","unstructured":"Makkar R.; Price M.; Lill M.; Takizawa K.; Frantzen M.; Fishbein M.; Eds ; Multilineage differentiation of transplanted allogenic mesenchymal stem cells injected in a porcine model of recent myocardial infarction improves left ventricular function. 2002"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S0735-1097(01)01248-7","volume":"37","author":"Lipsic E.","year":"2001","unstructured":"Lipsic E.; Protective effects of erythropoietin in cardiac ischemia from bench to bedside. J Am Coll Cardiol 2001,37,1775-1780","journal-title":"J Am Coll Cardiol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1093\/eurheartj\/ehl044","volume":"27","author":"Hamed S.","year":"2006","unstructured":"Hamed S.; Barshack I.; Luboshits G.; Wexler D.; Deutsch V.; Keren G.; George J.; Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy. Eur Heart J 2006,27(15),1876-1883","journal-title":"Eur Heart J"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10557-006-7680-5","volume":"20","author":"Lip\u0161ic E.","year":"2006","unstructured":"Lip\u0161ic E.; van der Meer P.; Voors A.A.; Westenbrink B.D.; van den Heuvel A.F.; de Boer H.C.; van Zonneveld A.J.; Schoemaker R.G.; van Gilst W.H.; Zijlstra F.; van Veldhuisen D.J.; A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: A randomized feasibility and safety study. Cardiovasc Drugs Ther 2006,20(2),135-141","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1159\/000176912","volume":"86","author":"Freimark D.","year":"1995","unstructured":"Freimark D.; Matetzky S.; Hod H.; Chouragui P.; Kaplinsky E.; Rabinowitz B.; High early peak creatine kinase after thrombolysis in patients with acute anterior infarction predicts poor left ventricular function. Cardiology 1995,86(5),411-416","journal-title":"Cardiology"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1093\/clinchem\/48.9.1432","volume":"48","author":"Panteghini M.","year":"2002","unstructured":"Panteghini M.; Cuccia C.; Bonetti G.; Giubbini R.; Pagani F.; Bonini E.; Single-point cardiac troponin T at coronary care unit discharge after myocardial infarction correlates with infarct size and ejection fraction. Clin Chem 2002,48(9),1432-1436","journal-title":"Clin Chem"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0002-9149(88)91294-5","volume":"61","author":"van der Laarse A.","year":"1988","unstructured":"van der Laarse A.; Kerkhof P.L.; Vermeer F.; Serruys P.W.; Hermens W.T.; Verheugt F.W.; B\u00e4r F.W.; Krauss X.H.; van der Wall E.E.; Simoons M.L.; Relation between infarct size and left ventricular performance assessed in patients with first acute myocardial infarction randomized to intracoronary thrombolytic therapy or to conventional treatment. Am J Cardiol 1988,61(1),1-7","journal-title":"Am J Cardiol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1253\/circj.CJ-10-0109","volume":"74","author":"Ozawa T.","year":"2010","unstructured":"Ozawa T.; Toba K.; Suzuki H.; Kato K.; Iso Y.; Akutsu Y.; Kobayashi Y.; Takeyama Y.; Kobayashi N.; Yoshimura N.; Akazawa K.; Aizawa Y.; EPO\/AMI-I Pilot Study Researchers. Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction-randomized controlled pilot trial of EPO\/AMI-1 study. Circ J 2010,74(7),1415-1423","journal-title":"Circ J"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/184249","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/184249\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/184249","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T13:51:46Z","timestamp":1638971506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/184249\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,14]]},"references-count":60,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2021,1,14]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389557520999200728155543","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,14]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-08-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}